Immediate Impact

25 standout
Sub-graph 1 of 8

Citing Papers

Enhancing Therapy Adherence: Impact on Clinical Outcomes, Healthcare Costs, and Patient Quality of Life
2025 Standout
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
2 intermediate papers

Works of Helen Moon being referenced

Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.
2023
A pharmacist based intervention to improve the care of patients with CKD: a pragmatic, randomized, controlled trial
2015

Author Peers

Author Last Decade Papers Cites
Helen Moon 74 61 43 25 164
Do-Kyong Kim 54 133 66 24 256
Mudassar Hussain 26 39 43 37 167
Sharon Peacock Hinton 41 142 47 24 272
Jong Soo Lee 58 76 42 29 287
Anna Rachelle Mislang 30 119 56 25 264
Sailesh Lodha 95 28 24 24 268
Afshan Zahedi 65 35 10 16 294
Fabio Robusto 65 51 17 22 232
C Pernot 31 20 13 28 148
Masayuki Nakashima 141 134 104 30 290

All Works

Loading papers...

Rankless by CCL
2026